CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis AG v. Apotex Inc.

1:15-cv-00975

Overview

Case Number 1:15-cv-00975
Filing Date 2015-10-26
Status Terminated
Termination Date 2017-06-09
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Apotex Corp. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Apotex Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Mitsui Sugar Co., Ltd. NPE (University / Research)

Represented By

0 Attorneys Listed
No attorneys available

Mitsubishi Tanabe Pharma Corporation NPE (University / Research)

Represented By

0 Attorneys Listed
No attorneys available

Novartis Pharmaceuticals Corporation Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Novartis AG Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 7 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (7): πŸ‡―πŸ‡΅ Japan πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5604229
2-amino-1,3-propanediol compound and immunosuppressant
Filed: 1993-10-18
Issued: 1997-02-18
Expired (Term Ended) +1949d PTA
Expires: 2019-02-18

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1949 days) / Cellect Scrutiny β€” Over 1949 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

8

Dispositive

7

Granted

0

Denied

1

Pending / Review

7

Motions by Category

Claim Construction / Markman Filing 1 Motion to Dismiss 7

Key Dispositive Motions & Rulings

Motion to Dismiss Denied
ORAL ORDER: IT IS HEREBY ORDERED THAT (1) Defendant's Motion to Dismiss for Lack of Standing (C.A. No. 14-1487 D.I. 62) is DENIED WITHOUT PREJUDICE to renew, co...
Entry #45 • 2016-03-14 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of (104 in 1:15-cv-00150-LPS, 42 in 1:15-cv-00975-LPS, 102 in 1:14-cv-01487-LPS, 129 in 1:15-cv-00151-LPS) Letter, to The Honorable Leonard P. ...
Entry #44 • 2016-03-09 Document →
Motion to Dismiss Pending / Under Review
[SEALED] Letter to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding Response to Plaintiffs' March 2, 2016 Letter on Discovery Disputes Relati...
Entry #42 • 2016-03-04 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of (94 in 1:14-cv-01487-LPS, 118 in 1:15-cv-00151-LPS, 94 in 1:15-cv-00150-LPS, 33 in 1:15-cv-00975-LPS) Letter to The Honorable Leonard P. Sta...
Entry #38 • 2016-03-03 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of (37 in 1:15-cv-00975-LPS, 100 in 1:15-cv-00150-LPS, 98 in 1:14-cv-01487-LPS, 124 in 1:15-cv-00151-LPS) Letter, Letter to The Honorable Leona...
Entry #39 • 2016-03-03 Document →
Motion to Dismiss Pending / Under Review
[SEALED] Letter to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding Discovery Disputes Related to Defendants' Motion to Dismiss - re (34 in 1...
Entry #37 • 2016-03-02 Document →

Docket Entries

(60 total)
Pleading / Complaint

COMPLAINT filed against Apotex Corp., Apotex Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1814972.) - filed by Novartis AG, Mitsui Sugar Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(sec) (Entered: 10/27/2015)

Entry #1 • 2015-10-26
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sec) (Entered: 10/27/2015)

Entry #2 • 2015-10-26
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/14/2015. Date of Expiration of Patent: 02/18/2019.Thirty Month Stay Deadline: 3/18/2018. (sec) (Entered: 10/27/2015)

Entry #3 • 2015-10-26
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,604,229. (sec) (Entered: 10/27/2015)

Entry #4 • 2015-10-26
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mitsubishi Chemical Holdings Corporation for Mitsubishi Tanabe Pharma Corporation filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co., Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (sec) (Entered: 10/27/2015)

Entry #5 • 2015-10-26
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc